Skip to main content
. 2021 Jun 25;10(7):1601. doi: 10.3390/cells10071601

Figure 4.

Figure 4

Enteric formulated 3-IAld protects from gut pathology in CF. Cftr F508del/F508del mice were infected with C. albicans and treated with 18 mg/kg of 3-IAld-MP given orally three times the week before the infection. (A) PAS staining of the colon, ileum and liver; (B) expression of Ki67 and ZO-1 in the colon; expression of (C) Il22; (D) inflammatory and anti-inflammatory cytokines; (E) antimicrobial peptide LL37 and defensins by RT-PCR in the ileum and colon. Assays were done 7 days after the infection. For immunofluorescence, nuclei were counterstained with DAPI. Photographs were taken using a high-resolution Olympus DP71 microscope using an 20× objective. Scale bar 200 μm. Values represent the mean ± SD of four mice per group or are representative of three experiments. Naïve, uninfected mice; None, infected mice. * p < 0.05; ** p < 0.01; *** p < 0.001; **** p < 0.0001, one-way ANOVA—Bonferroni’s, 3-IAld-MP vs. None.